Progress and development of small molecule HCV antivirals

Area of Science:

• Hepatology
• Virology
• Medicinal Chemistry

Background:

• Chronic Hepatitis C virus (HCV) infection impacts global health.
• Current interferon-alpha (IFN-alpha) and ribavirin therapy has limited efficacy and significant side effects.
• Development of novel antiviral strategies is crucial for effective HCV control.

Purpose of the Study:

• To review recent advancements in small molecule antiviral agents for Hepatitis C virus (HCV) infection.
• To discuss the potential of NS3/4A serine protease and NS5B polymerase inhibitors.
• To evaluate emerging therapeutic approaches beyond standard combination therapy.

Main Methods:

• Review of preclinical and clinical trial data for HCV NS3/4A protease inhibitors.
• Analysis of research on nucleoside and non-nucleoside NS5B polymerase inhibitors.
• Synthesis of information on peptidomimetic product-based approaches.

Main Results:

• Proof-of-concept clinical trials for NS3/4A protease inhibitor BILN-2061 demonstrate therapeutic potential.
• Peptidomimetic strategies are advancing the development of improved protease inhibitors.
• Preclinical data for HCV polymerase inhibitors (nucleoside and non-nucleoside) are encouraging.

Conclusions:

• Small molecule inhibitors targeting HCV NS3/4A protease and NS5B polymerase represent promising therapeutic avenues.
• Advancements in peptidomimetic design and polymerase inhibition offer new hope for HCV treatment.
• Further research into these novel antivirals could lead to more effective and safer options for chronic HCV infection.